coronary stenosis

POKI: una nueva estrategia en bifurcaciones

Long-term Results of Coronary Bifurcation Lesion Treatment in Diabetic Patients

The effects of diabetes on patients with coronary artery disease are well-known, and their outcomes after angioplasty are less favorable, with a higher rate of restenosis, recurrent acute myocardial infarction, and stent thrombosis. Despite advances in drug-eluting stents and procedural techniques, the treatment of coronary bifurcation lesions in diabetic patients shows less positive clinical outcomes<a href="https://solaci.org/en/2024/01/18/long-term-results-of-coronary-bifurcation-lesion-treatment-in-diabetic-patients/" title="Read more" >...</a>

Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions

Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this strategy have shown clinical outcomes comparable to drug-eluting stents’ (DES) in patients with in-stent restenosis and&nbsp;de novo&nbsp;disease in small vessels. However, evidence for the use of DCB in large coronary vessels is limited. This observational, retrospective study DCB<a href="https://solaci.org/en/2023/12/21/outcomes-of-the-use-of-drug-coated-balloons-in-the-treatment-of-de-novo-coronary-lesions/" title="Read more" >...</a>

La ATC es una alternativa válida en el TCI

Revascularization vs. Deferral of Physiologically Significant Lesions in the Left Main Coronary Artery

Most randomized studies on decision-making in coronary artery disease revascularization exclude left main coronary artery disease (LMCAD), as did the ISCHEMIA Study. On the other hand, the benefits of functionally assessing lesions, proven in studies such as FAME, emphasize the importance of this tool in guiding revascularization decisions. However, there is still little understanding of<a href="https://solaci.org/en/2023/12/06/revascularization-vs-deferral-of-physiologically-significant-lesions-in-the-left-main-coronary-artery/" title="Read more" >...</a>

¿Es frecuente el uso de IVUS para guiar la ATC?

Can Ultrasound Treat Aortic Stenosis?

Severe calcified aortic stenosis is a common condition that can currently be effectively treated with SAVR or TAVR. However, some patients, given comorbidities or anatomical characteristics, are not good candidates for these therapeutic alternatives.&nbsp; The non-invasive ultrasound therapy (NIUT) has surged as viable alternative. It claims ultrasound might act on calcified valves, and mobilize tissue<a href="https://solaci.org/en/2023/12/05/can-ultrasound-treat-aortic-stenosis/" title="Read more" >...</a>

¿Es la litotricia coronaria tan efectiva como la aterectomía rotacional?

Is Coronary Lithotripsy as Effective as Rotational Atherectomy?

Severely calcified lesions currently pose a significant challenge, as they require adequate preparation through non-compliant balloons or cutting balloons to achieve effective stent expansion. Another option is the use of orbital or rotational atherectomy (RA), but this carries the risk of complications such as slow/no reflow, perforations, dissections, peri-procedural infarction, or guidewire rupture. Despite the<a href="https://solaci.org/en/2023/11/23/is-coronary-lithotripsy-as-effective-as-rotational-atherectomy/" title="Read more" >...</a>

Impella

Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as we know, is associated with coronary artery disease (CAD) approximately in 50% of cases. In high risk surgical patients, this calls for procedures such as percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR).&nbsp;&nbsp; PCI with ventricular<a href="https://solaci.org/en/2023/11/08/impella-in-high-risk-coronary-angioplasty-before-tavr/" title="Read more" >...</a>

TCT 2023 | ALIGN AR trial

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).&nbsp; Primary end point was late lumen loss (LLL) at 12 months.&nbsp; There were no significant differences between the groups. Mean patient age was 63, 75% were<a href="https://solaci.org/en/2023/10/30/tct-2023-in-stent-restenosis-sirolimus-vs-paclitaxel-coated-balloons/" title="Read more" >...</a>

Resultado a 3 años luego de ATC con técnica de 2- stents vs Provisional stent por bifurcaciones complejas

Treatment and Gender-Based Outcomes for Coronary Bifurcation Stent Placement: Report from the e-ULTIMASTER Registry

Approximately 20% of all percutaneous coronary interventions (PCI) are performed on bifurcation lesions, which continue to pose a challenge in terms of strategy: how many stents to use, what is the most suitable strategy, and when to transition from a single stent to two during the procedure. Additionally, the use of two stents in these<a href="https://solaci.org/en/2023/10/06/treatment-and-gender-based-outcomes-for-coronary-bifurcation-stent-placement-report-from-the-e-ultimaster-registry/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Use of Drug-Coated Balloons in De Novo Lesions in Large Coronary Vessels

Drug-coated balloon (DCB) angioplasty is emerging as a novel treatment for coronary artery disease. Studies evaluating this strategy have demonstrated clinically non-inferior outcomes compared with those of drug-eluting stent (DES) implantation in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCBs in large coronary vessels is<a href="https://solaci.org/en/2023/09/28/use-of-drug-coated-balloons-in-de-novo-lesions-in-large-coronary-vessels/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

EASTBOURNE Registry: Use of Sirolimus-Coated Balloons in Coronary Artery Disease

The introduction of drug coated balloons (DCB) has become an innovative therapeutic alternative to current treatments. Paclitaxel-coated balloons (PCB) have been used to treat in-stent restenosis (ISR) and also approach CAD in native arteries. More recently, sirolimus-coated balloons (SCB) are being looked at as part of pilot studies and smaller registries with preliminary results.&nbsp; The<a href="https://solaci.org/en/2023/08/23/eastbourne-registry-use-of-sirolimus-coated-balloons-in-coronary-artery-disease/" title="Read more" >...</a>

Top